

## Starting June 1, we're replacing Stelara with biosimilar drugs for most Medicare Advantage members

Effective June 1, 2025, Medicare Plus Blue and BCN Advantage plans will stop covering Stelara<sup>®</sup> and will instead cover the biosimilars Wezlana<sup>™</sup> and Yesintek<sup>™</sup> in its place.

**Note:** UAW Retiree Medical Benefits Trust plan members won't be affected.

Current Stelara users have received new authorizations for Wezlana and Yesintek so they can continue therapy without interruption. The U.S. Food and Drug Administration has already approved Wezlana and Yesintek as interchangeable biosimilars to Stelara. A new prescription isn't required for interchangeable biosimilars.

When submitting a prior authorization request for a new patient, select one of the following preferred products:

Preferred ustekinumab products	National Drug Codes
Wezlana SC solution 45 mg/0.5 mL	84612-0855-01
Wezlana prefilled syringe 45 mg/0.5 mL	84612-0876-01
Wezlana prefilled syringe 90 mg/mL	84612-0889-01
Yesintek prefilled syringe 45 mg/0.5 mL	83257-0023-41
Yesintek SC solution 45 mg/0.5 mL	83257-0024-11
Yesintek prefilled syringe 90 mg/mL	83257-0025-41

For a complete list of drugs and associated requirements, go to [2025 Drug Lists](#) for Medicare Members.

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.